Mitsubishi Tanabe Pharma America Shares Key Parkinson’s Insights
Mitsubishi Tanabe Pharma America Highlights Parkinson's Disease Research
Mitsubishi Tanabe Pharma America, Inc. (MTPA) has recently announced that it will present significant research on an investigational treatment for Parkinson's disease (PD) at two important upcoming congresses. This exciting development centers around their innovative therapy, ND0612, which is designed as a continuous subcutaneous infusion of liquid levodopa/carbidopa. MTPA will share their findings at the European Academy of Neurology (EAN) congress and the Advanced Therapeutics in Movement & Related Disorders Congress (ATMRD).
Upcoming Presentation Insights on ND0612
At the EAN congress, scheduled to take place over several days, MTPA will present an e-poster detailing the effects of ND0612 on OFF and ON episodes among patients with PD. The data originates from the pivotal Phase 3 BouNDless study, which aims to assess treatment efficacy in reducing motor fluctuations experienced by those living with Parkinson's.
Presentation Overview
- Effect of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (Investigational ND0612) on Motor Fluctuations by Joaquim J. Ferreira, M.D., Ph.D.; University of Lisbon
ePoster #EPR-052, Movement Disorders 1 Session: 2:35-2:40 p.m. EEST, June 21
Findings at the ATMRD Congress
Following EAN, MTPA will be at the ATMRD congress, where they will focus on the findings from their Phase 3 BouNDless trial. This session will particularly highlight outcomes based on patient-reported experiences regarding quality of life improvements for those receiving the ND0612 treatment for motor fluctuations.
Additional Research Highlights
- Dopaminergic Adverse Events With 24-hour Subcutaneous Infusion of Investigational ND0612 by Huyen Phan, Pharm.D.; MTPA
Poster #P42 - Quality of Life With 24-hour Subcutaneous Levodopa/Carbidopa Infusion (Investigational ND0612): QoL Results from a Phase 3, Randomized Study by Amanda Goldberg, MPAS, PA-C; MTPA
Poster #P412 - Long-Term Efficacy of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (Investigational ND0612) for Motor Fluctuations in Parkinson's Disease by Rajesh Pahwa, M.D., FAAN; University of Kansas Medical Center
Poster #P32
About ND0612
ND0612 represents a cutting-edge investigational drug-device combination, aiming to enhance treatment for individuals grappling with motor fluctuations attributed to Parkinson's disease. Developed by NeuroDerm Ltd., under the umbrella of Mitsubishi Tanabe Pharma Corporation (MTPC), this therapy reflects MTPA's commitment to advancing the treatment landscape for PD.
About Mitsubishi Tanabe Pharma America, Inc.
Mitsubishi Tanabe Pharma America is a dedicated subsidiary of Mitsubishi Tanabe Pharma Corporation, focused on the North American market. Established to innovate and advance pharmaceutical products, MTPA strives to bring meaningful therapies to patients, showcasing its commitment to addressing unmet medical needs.
About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation has a long-standing legacy, tracing its origins back to 1678. With its headquarters in Osaka, Japan, MTPC champions ethical pharmaceuticals across several therapeutic areas, including central nervous system disorders, immuno-inflammation, diabetes, kidney care, and oncology. The corporation is deeply invested in precision medicine, aiming to deliver therapies that align with the individual needs of patients.
About NeuroDerm Ltd.
NeuroDerm Ltd., a wholly-owned subsidiary of MTPC based in Israel, is committed to developing innovative drug-device combination therapies. Focused on enhancing the quality of life for patients with central nervous system conditions, NeuroDerm is progressing with its transformative therapeutic approaches aimed at improving disease management.
Frequently Asked Questions
What does ND0612 aim to treat?
ND0612 aims to treat motor fluctuations in patients with Parkinson's disease through continuous subcutaneous infusion.
Where will MTPA present its research?
MTPA will present its research at both the EAN congress and the ATMRD congress.
What are the dates for the EAN congress?
The EAN congress is scheduled for June 21-24, 2025.
Who is leading the development of ND0612?
The development of ND0612 is being led by NeuroDerm Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation.
What is the focus of Mitsubishi Tanabe Pharma Corporation?
Mitsubishi Tanabe Pharma Corporation focuses on various therapeutic areas, including central nervous system disorders and precision medicine to enhance patient care.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
